42 citations
,
July 2021 in “Frontiers in Medicine” In this study, proxalutamide significantly reduced the 30-day hospitalization rate by 91% compared to placebo in men with COVID-19 treated in outpatient settings.
41 citations
,
February 2021 in “Cureus” In this study, Proxalutamide significantly increased the rate of viral clearance and reduced clinical remission time in patients with mild to moderate COVID-19 compared to placebo.
28 citations
,
October 1992 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” In this study, Scalp Immersion Proxigraphy (SIP) was shown to produce more accurate measurements of linear hair growth rate than crude phototrichogram techniques, suggesting SIP's suitability for clinical trials monitoring hair growth.
19 citations
,
December 2021 in “Cureus” This study found that proxalutamide significantly increased recovery rates, reduced mortality, and shortened hospital stays in hospitalized COVID-19 patients across different regions in Brazil.
5 citations
,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” This study found that proxalutamide improved immunologic, inflammatory, thrombotic, and oxygen markers in both female and male COVID-19 outpatients, which may support its association with lower hospitalization rates compared to standard care.